Virus vaccines: proteins prefer prolines.
Reads0
Chats0
TLDR
In this paper, the structure-guided introduction of proline residues at key positions that maintain the trimer in the pre-fusion configuration has been used to enhance stability and presentation of these NAb epitopes.About:
This article is published in Cell Host & Microbe.The article was published on 2021-03-10 and is currently open access. It has received 53 citations till now. The article focuses on the topics: Viral Vaccine & Viral envelope.read more
Citations
More filters
Journal ArticleDOI
SARS-CoV-2 Variants, Vaccines, and Host Immunity
Priyal Mistry,Fatima Barmania,Juanita Mellet,Kimberly Thando Peta,A. Strydom,Ignatius M. Viljoen,William James,Siamon Gordon,Michael S. Pepper +8 more
TL;DR: In this article , the authors reviewed both SARS-CoV-2-induced host immune activation and vaccine-induced immune responses, highlighting the responses of immune memory cells that are key indicators of host immunity.
Journal ArticleDOI
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects.
TL;DR: The development of effective vaccines to combat infectious diseases is a complex multi-year and multi-stakeholder process as mentioned in this paper, and the success of the endeavor can be seen in the rapid advanced development of multiple vaccine candidates.
Journal ArticleDOI
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Satoshi Ikegame,Mohammed N. A. Siddiquey,Chuan-Tien Hung,Griffin Haas,Luca Brambilla,Kasopefoluwa Y. Oguntuyo,Shreyas Kowdle,Hsin-Ping Chiu,Christian S. Stevens,Ariel Esteban Vilardo,Alexis Edelstein,Claudia Perandones,Jeremy P. Kamil,Benhur Lee +13 more
TL;DR: In this paper, the authors characterize the neutralizing activity of post-Sputnik V vaccination sera against the ensemble of S mutations present in alpha (B.1.7) and beta (B1.351) VOCs, showing the latter to exhibit resistance to neutralization in vitro.
Journal ArticleDOI
Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study
Marit J. van Gils,A.H. Ayesha Lavell,Karlijn van der Straten,Brent Appelman,Ilja Bontjer,Meliawati Poniman,Judith A. Burger,Melissa Oomen,J. H. Bouhuijs,Lonneke A. van Vught,Marleen A. Slim,Michiel Schinkel,Elke Wynberg,Hugo D.G. van Willigen,Marloes Grobben,Khadija Tejjani,J. van Rijswijk,Jonne L. Snitselaar,Tom G. Caniels,Alexander P.J. Vlaar,Maria Prins,Menno D. de Jong,Godelieve J. de Bree,Jonne J. Sikkens,Marije K. Bomers,Rogier W. Sanders +25 more
TL;DR: Overall, this study shows that the mRNA vaccines appear superior to adenovirus vector-based vaccines in inducing neutralizing antibodies against VOCs four weeks after initial vaccination and after booster vaccination, which implies the use of mRNA vaccines for both initial and booster vaccination.
Journal ArticleDOI
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge.
Anthony T. DiPiazza,Sarah R. Leist,Olubukola M. Abiona,Juan I. Moliva,Anne P. Werner,Mahnaz Minai,Bianca M. Nagata,Kevin W. Bock,Emily Phung,Alexandra Schäfer,Kenneth H. Dinnon,Lauren A. Chang,Rebecca J. Loomis,Seyhan Boyoglu-Barnum,Gabriela S. Alvarado,Nancy J. Sullivan,Darin K. Edwards,Kaitlyn M. Morabito,John R. Mascola,Andrea Carfi,Kizzmekia S. Corbett,Ian N. Moore,Ralph S. Baric,Barney S. Graham,Tracy J. Ruckwardt +24 more
TL;DR: This article used the SARS coronavirus 2 (SARS-CoV-2) mouse-adapted, passage 10, lethal challenge virus (MA10) model of acute lung injury to evaluate the immune response and potential for immunopathology in animals vaccinated with research-grade mRNA-1273.
References
More filters
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.
Daniel Wrapp,Nianshuang Wang,Kizzmekia S. Corbett,Jory A. Goldsmith,Ching-Lin Hsieh,Olubukola M. Abiona,Barney S. Graham,Jason S. McLellan +7 more
TL;DR: The authors show that this protein binds at least 10 times more tightly than the corresponding spike protein of severe acute respiratory syndrome (SARS)–CoV to their common host cell receptor, and test several published SARS-CoV RBD-specific monoclonal antibodies found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.
Journal ArticleDOI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Merryn Voysey,Clemens Sac.,Shabir A. Madhi,Lily Yin Weckx,P M Folegatti,Parvinder K. Aley,Brian Angus,Vicky L. Baillie,Shaun Barnabas,Q E Bhorat,S Bibi,Carmen Briner,P Cicconi,Andrea M. Collins,R Colin-Jones,Clare L. Cutland,Thomas C. Darton,Keertan Dheda,Duncan Cja.,Emary Krw.,Katie J. Ewer,Lee Fairlie,Saul N. Faust,Shuo Feng,Daniela M. Ferreira,Adam Finn,Anna Goodman,Catherine M. Green,Christopher A Green,Paul T. Heath,Christopher Hill,Helen Hill,Ian Hirsch,Hodgson Shc.,Allen Izu,S Jackson,D Jenkin,Joe Ccd.,S Kerridge,Anthonet Koen,Gaurav Kwatra,Rajeka Lazarus,Alison M. Lawrie,A Lelliott,Vincenzo Libri,Patrick J. Lillie,R Mallory,Mendes Ava.,Eveline Pipolo Milan,Angela M. Minassian,Alastair McGregor,Hazel Morrison,Y Mujadidi,Amit J Nana,P J O’Reilly,S D Padayachee,A Pittella,E Plested,Katrina M Pollock,M N Ramasamy,S Rhead,Alexandre Vargas Schwarzbold,Nisha Singh,Andrew Smith,R Song,Matthew D. Snape,Eduardo Sprinz,Rebecca K. Sutherland,R Tarrant,E. Thomson,M E Török,Mark Toshner,Turner Dpj.,Johan Vekemans,Tonya Villafana,Watson Mee.,C J Williams,Alexander D. Douglas,Hill Avs.,Teresa Lambe,Sarah C. Gilbert,Andrew J. Pollard +81 more
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI
SARS-CoV-2 vaccines in development.
TL;DR: The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
Journal ArticleDOI
DNA vaccine protection against SARS-CoV-2 in rhesus macaques.
Jingyou Yu,Lisa H. Tostanoski,Lauren Peter,Noe B. Mercado,Katherine McMahan,Shant H. Mahrokhian,Joseph P. Nkolola,Jinyan Liu,Zhenfeng Li,Abishek Chandrashekar,David R. Martinez,Carolin Loos,Caroline Atyeo,Stephanie Fischinger,John S. Burke,Matthew D. Slein,Yuezhou Chen,Adam Zuiani,Felipe J.N. Lelis,Meghan Travers,Shaghayegh Habibi,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Renita Brown,Anthony Cook,Brad Finneyfrock,Alan Dodson,Elyse Teow,Jason Velasco,Roland Zahn,Frank Wegmann,Esther A. Bondzie,Gabriel Dagotto,Makda S. Gebre,Xuan He,Catherine Jacob-Dolan,Marinela Kirilova,Nicole Kordana,Zijin Lin,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,John D. Ventura,Huahua Wan,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Duane R. Wesemann,Ralph S. Baric,Galit Alter,Hanne Andersen,Mark G. Lewis,Dan H. Barouch,Dan H. Barouch +54 more
TL;DR: Analysis of the vaccine candidates in rhesus macaques showed that animals developed protective humoral and cellular immune responses when challenged with the SARS-CoV-2 virus, suggesting an immune correlate of protection.
Related Papers (5)
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Jesper Pallesen,Nianshuang Wang,Kizzmekia S. Corbett,Daniel Wrapp,Robert N. Kirchdoerfer,Hannah L. Turner,Christopher A. Cottrell,Michelle M. Becker,Lingshu Wang,Wei Shi,Wing-Pui Kong,Erica L. Andres,Arminja N. Kettenbach,Mark R. Denison,Mark R. Denison,James D. Chappell,Barney S. Graham,Andrew B. Ward,Jason S. McLellan +18 more
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Lindsey R. Baden,Hana M. El Sahly,Brandon Essink,Karen L. Kotloff,Sharon E. Frey,Rick Novak,David Diemert,Stephen A. Spector,Nadine Rouphael,C. Buddy Creech,John W McGettigan,Shishir Khetan,Nathan Segall,Joel Solis,Adam Brosz,Carlos Fierro,Howard J. Schwartz,Kathleen M. Neuzil,Lawrence Corey,Peter B. Gilbert,Holly Janes,Dean Follmann,Mary A. Marovich,John R. Mascola,Laura Polakowski,Julie E. Ledgerwood,Barney S. Graham,Hamilton Bennett,Rolando Pajon,Conor Knightly,Brett Leav,Weiping Deng,Honghong Zhou,Shu Liang Han,Melanie Ivarsson,Jacqueline Miller,Tal Z Zaks +36 more